Lipocine Announces Presentations on TLANDO at ENDO 2021 Conference

Lipocine Announces Presentations on TLANDO

at ENDO 2021 Conference

LAKE CITY, March 3, 2021-- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on

metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO will be presented at

the ENDO 2021 Conference, to take place March 20-23, 2021. TLANDO is an oral testosterone replacement therapy

("TRT") product candidate being developed for adult males with conditions associated with a deficiency or absence

of endogenous testosterone, also known as hypogonadism.

March 20, 2021 11:00 a.m. E.T., On-Demand

March 20, 2021 11:00 a.m. E.T., On-Demand

March 20, 2021 11:00 a.m. E.T., On-Demand

Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery

technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO,

a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions

associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug

of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the

treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel

oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with

potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met

the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment

of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention

of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.

This release contains "forward-looking statements"

that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements

that are not historical facts regarding Lipocine's product candidates and related clinical trials, the timing of completion of

clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential

uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking

statements involve risks and uncertainties, including, without limitation, the risk that the FDA will not approve any of our products,

risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not

being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt

of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing

and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without

limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov.

Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as

President & Chief Financial Officer

Phone: (801) 994-7383

Phone: (617) 535-7743